Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

被引：5

作者：

Ramalingam, Suresh S. ^{[1
]}

Saka, Hideo ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Yu, Helena ^{[4
]}

Horn, Leora ^{[5
]}

Hida, Toyoaki ^{[6
]}

Cantarini, Mireille ^{[7
]}

Verheijen, Remy ^{[7
]}

Wessen, Jonathan ^{[7
]}

Oxnard, Geoffrey ^{[8
]}

Ohe, Yuichiro ^{[9
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan

[3] Samsung Med Ctr, Seoul, South Korea

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Aichi Canc Ctr, Nagoya, Aichi, Japan

[7] Astrazeneca, Global Med Dev, Cambridge, England

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Natl Canc Ctr, Tokyo, Japan

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT034

引用

页数：2

共 50 条

[21] Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Hirashima, T.
Yoh, K.
Saka, H.
Kurata, T.
Ohe, Y.
Hida, T.
Mellemgaard, A.
Verheijen, R. B.
Ou, X.
Hayama, M.
Sugibayashi, K.
Oxnard, G.
ANNALS OF ONCOLOGY, 2020, 31 : S1393 - S1393
[22] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
Xu, Qinghua
Liu, Hui
Meng, Shuyan
Jiang, Tao
Li, Xuefei
Liang, Shixiong
Ren, Shengxiang
Zhou, Caicun
JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
[23] Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC
Qin, Bao-Dong
Jiao, Xiao-Dong
Wang, Yan
Wu, Ying
Ling, Yan
Liu, Ke
Zang, Yuan-Sheng
LUNG CANCER, 2022, 170 : 91 - 97
[24] Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
Lu, S.
Cheng, Y.
Wu, L.
Fang, J.
Li, B.
Han, L.
Zhang, Y.
Pan, H.
Wang, Z.
Sun, Y.
Ye, F.
Hu, Y.
Yu, W.
Zhou, H.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S649
[25] Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study
Akamatsu, Hiroaki
Koh, Yasuhiro
Ozawa, Yuichi
Fujimoto, Daichi
Hata, Akito
Katakami, Nobuyuki
Tomii, Keisuke
Shimokawa, Toshio
Yamamoto, Nobuyuki
CLINICAL LUNG CANCER, 2018, 19 (06) : E871 - E874
[26] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
Liam, C. K.
Ahmad, A. Rozila
Hsia, T.
Li, J. Y.
Le, X.
Heymach, J.
Yang, J. C.
Soo, R.
Zhang, Y.
Kim, S.
Shin, S. W.
Johne, A.
Karachaliou, N.
Bruns, R.
Ellers-Lenz, B.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
[27] Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
Bischoff, H. G.
Rueckert, A.
Reinmuth, N.
Grohe, C.
Bohnet, S.
zum Bueschenfelde, C. M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 187 - 187
[28] Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC
Zhu, Y.
Chen, Y.
Han, S.
Ying, X.
Sun, X.
Xu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S502 - S502
[29] TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Oxnard, G. R.
Yang, J. C. -H.
Yu, H.
Kim, S. -W.
Saka, H.
Horn, L.
Goto, K.
Ohe, Y.
Mann, H.
Thress, K. S.
Frigault, M. M.
Vishwanathan, K.
Ghiorghiu, D.
Ramalingam, S. S.
Ahn, M. -J.
ANNALS OF ONCOLOGY, 2020, 31 (04) : 507 - 516
[30] Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors
Chen, Y-Y.
Zhu, Q-Q.
Dai, L-J.
Ding, Z-Y.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →